Author:
Kathiravelu Kaameny,Samsudin Intan Nureslyna,Mat Salleh Mohd Jamsani,C. Thambiah Subashini
Abstract
Introduction: Thyroglobulin (Tg) measurement is important for detection of disease recurrence in patients with differentiated thyroid carcinoma (DTC). However, its measurement is affected by Tg autoantibodies (TgAb). Calculation of Tg recovery may complement quantitative TgAb measurement in detection of interference. This study aimed to determine the prevalence of TgAb positivity in Tg samples received from post-thyroidectomy DTC patients in Hospital Pulau Pinang (HPP). Additionally, we assessed the use of the Tg II Confirmatory Test (Roche Diagnostics) assay to calculate Tg recovery in detecting Tg assay interference. Method: Samples received for Tg measurements from post-thyroidectomy DTC patients with TgAb positivity were tested with Tg II Confirmatory Test. The Tg levels [categorised as biochemically detectable (≥1.0 μg/l) vs biochemically undetectable (<1.0 μg/l)], TgAb and Tg recovery [categorised as correct (70%-130%) vs compromised (<70% and >130%) recovery] were interpreted with the diagnostic radioiodine uptake (RAI) results. Results: In this study, 58/73 (79.5%) samples with TgAb positivity had undetectable Tg. A compromised Tg recovery was observed in three (4.1%) samples. Only 51 out of 73 subjects had an RAI performed, out of which 27 (52.9%) had increased RAI uptake (radiological evidence of persistent/recurrent disease). Of those with increased RAI uptake, 17 (63%) had biochemically undetectable Tg, out of which none had compromised Tg recovery. Conclusion: The presence of TgAb prevents reliable measurement of Tg. The Tg II Confirmatory assay for calculation of Tg recovery did not provide additional complementary value to quantitative TgAb measurement in the detection of interference in Tg measurements.
Publisher
Universiti Putra Malaysia
Reference16 articles.
1. 1. SEER Cancer Stat Facts: Thyroid Cancer. National Cancer Institute. Bethesda, MD, https://seer.cancer.gov/statfacts/html/thyro.html Accessed February 18, 2022
2. 2. Malaysia National Cancer Registry Report 2012-2016.
3. 3. Schmidbauer B, Menhart K, Hellwig D, Grosse J. Differentiated Thyroid Cancer-Treatment: State of the Art. Int J Mol Sci. 2017;18(6):1292. doi: 10.3390/ijms18061292.
4. 4. Schoonen L, Neele M, van Toor H, et al. Impact of Thyroglobulin and Thyroglobulin Antibody Assay Performance on the Differential Classification of DTC Patients. J Endocr Soc. 2021;10;6(1):bvab166. doi: 10.1210/jendso/bvab166.
5. 5. Perros P, Boelaert K, Colley S, et al. British Thyroid Association. Guidelines for the management of thyroid cancer. Clin Endocrinol (Oxf). 2014;81 Suppl 1:1-122. doi: 10.1111/cen.12515.